 Aurobindo
Pharma Ltd''s Unit XII facility at Hyderabad has received
approval from the UK''s Medicines and Healthcare products
Regulatory Agency (UK MHRA) to manufacture formulations
for the UK Market.
This
facility is among Aurobindo Pharma''s largest manufacturing
plants and manufactures the high-end betalactum range.
Spread over 15,228 sq meters, the plant can manufacture
dry powder injectables, powders for oral suspensions,
tablets and capsules.
This
unit also has also been certified by several overseas
health bodies including the US FDA, South African MCC
and Brazilian ANVISA besides meeting the ISO norms.
Aurobindo Pharma says that it has filed several dossiers
with European authorities for its APIs and formulations.
Earlier,
the UK MHRA had also approved the first formulation
of the
company''s sertraline. With the latest approval by the
UK MHRA''s
formulation facility, Aurobindo Pharma says establishing
a presence in the regulated markets has been smoothened.
|
